| answer text |
<p>The Joint Committee on Vaccination and Immunisation (JCVI) published interim advice
on a potential COVID-19 booster vaccination programme on 30 June 2021, which is available
at the following link:</p><p><a href="https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-interim-advice-potential-covid-19-booster-vaccine-programme-winter-2021-to-2022"
target="_blank">https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-interim-advice-potential-covid-19-booster-vaccine-programme-winter-2021-to-2022</a></p><p>As
stated in the interim advice, adults who are severely immunosuppressed, such as those
who have had solid organ transplants, may not respond as well to COVID-19 vaccines.
The advice states that those adults who are severely immunosuppressed should be offered
COVID-19 booster revaccination at the start of the booster programme. It should be
noted that this advice may be subject to change before being finalised.</p><p>Final
decisions on the timing and scope of the vaccine booster programme will be made later
in the year, informed by further independent advice from the JCVI. The JCVI will review
the emerging scientific evidence to inform the Government in our final decision-making
process, which includes further data on the durability of protection from vaccines,
data supplied by manufacturers and clinical trial data from the Cov-Boost trial on
immune responses following a third vaccination. It is anticipated that primary data
from the initial stages of this trial will be reported to the JCVI by the end of summer
2021.</p>
|
|
